CTLA4 and melanoma: In particular, a higher level of sPD‐L1 prior ICIs treatment (anti‐CTLA‐4/anti‐PD‐1 blockade), was more likely to suffer from progressive diseases and poorer clinical outcomes in different types of tumors, such as melanoma, NSCLC, breast cancer, and other solid tumors.166, 168, 171, 172, 173